康方生物(09926.HK)卡度尼利治疗高复发风险肝细胞癌三期临床完成患者入组

阿斯达克财经
Yesterday

康方生物(09926.HK) 宣布,自主研发的全球首创PD-1/CTLA-4双抗新药卡度尼利“开坦尼”,用于高复发风险肝细胞癌(HCC)根治术或消融后辅助治疗的注册性三期临床研究,近日已完成全部患者入组。
目前卡度尼利配合仑伐替尼和经肝动脉化疗栓塞(TACE)用于治疗中晚期不可切除HCC的注册三期临床研究也在进行中,公司预期,卡度尼利可望成为早期和中晚期HCC患者全方位且更有效率的疾病解决方案。

卡度尼利针对胃癌、肺癌、肝癌、子宫颈癌、胰脏癌等瘤种的16个适应症已经进行超过23项临床研究,针对复发/转移性子宫颈癌和第一线胃癌适应症已获批上市。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-05 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10